PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.

Abstract Protein arginine methyltransferase 5 is one of the type II protein arginine methyltransferase family members that can symmetrically dimethylate arginine residues on target proteins in both the cytoplasm and the nucleus. Protein arginine methyltransferase 5 was reported to be an oncoprotein that participates in tumor progression through both epigenetic silencing and organelle biogenesis. So far, it has been implicated in various cancers, but its expression pattern in breast cancer has not been elucidated thoroughly. We analyzed the protein arginine methyltransferase 5 expression patterns in several breast cancer samples and tissue arrays to better characterize its contribution to breast cancer. Primary breast tumors showed increased protein arginine methyltransferase 5 expression compared with adjacent normal tissues in both the fresh tissue samples and tissue arrays. Also, there was a tendency that metastatic lymph nodes demonstrated enhanced protein arginine methyltransferase 5 expression compared to primary sites. Moreover, we found a significant correlation between protein arginine methyltransferase 5 and Ki-67, with higher Ki-67 and protein arginine methyltransferase 5 expressions in primary breast tumors compared with normal breast tissues. Moreover, the Cancer Genome Atlas cohort analysis revealed that high protein arginine methyltransferase 5 messenger RNA expression was associated with an unfavorable prognosis in human epidermal growth factor receptor 2 (HER-2) positive and triple negative breast cancer patients. Finally, the roles and mechanisms of protein arginine methyltransferase 5 in the proliferation, cell cycle progression, and apoptosis of MDA-MB-231 cells were assessed using protein arginine methyltransferase 5 and shPRMT5 transfection. In conclusion, we proposed that protein arginine methyltransferase 5 is an independent prognostic biomarker for breast cancer, and targeting protein arginine methyltransferase 5 might be a promising strategy for breast cancer treatment.
PMID
Related Publications

Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein.

Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes.

PRMT2 and RORĪ³ expression are associated with breast cancer survival outcomes.

Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes.

Clinical evaluation of PRMT1 gene expression in breast cancer.

Authors

Mayor MeshTerms
Keywords

Breast cancer

apoptosis

cell cycle progression

proliferation

protein arginine methyltransferase 5

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28381188
OWN - NLM
STAT- MEDLINE
DA  - 20170406
DCOM- 20170418
LR  - 20170418
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 4
DP  - 2017 Apr
TI  - Elevated expression of protein arginine methyltransferase 5 predicts the poor
      prognosis of breast cancer.
PG  - 1010428317695917
LID - 10.1177/1010428317695917 [doi]
AB  - Protein arginine methyltransferase 5 is one of the type II protein arginine
      methyltransferase family members that can symmetrically dimethylate arginine
      residues on target proteins in both the cytoplasm and the nucleus. Protein
      arginine methyltransferase 5 was reported to be an oncoprotein that participates 
      in tumor progression through both epigenetic silencing and organelle biogenesis. 
      So far, it has been implicated in various cancers, but its expression pattern in 
      breast cancer has not been elucidated thoroughly. We analyzed the protein
      arginine methyltransferase 5 expression patterns in several breast cancer samples
      and tissue arrays to better characterize its contribution to breast cancer.
      Primary breast tumors showed increased protein arginine methyltransferase 5
      expression compared with adjacent normal tissues in both the fresh tissue samples
      and tissue arrays. Also, there was a tendency that metastatic lymph nodes
      demonstrated enhanced protein arginine methyltransferase 5 expression compared to
      primary sites. Moreover, we found a significant correlation between protein
      arginine methyltransferase 5 and Ki-67, with higher Ki-67 and protein arginine
      methyltransferase 5 expressions in primary breast tumors compared with normal
      breast tissues. Moreover, the Cancer Genome Atlas cohort analysis revealed that
      high protein arginine methyltransferase 5 messenger RNA expression was associated
      with an unfavorable prognosis in human epidermal growth factor receptor 2 (HER-2)
      positive and triple negative breast cancer patients. Finally, the roles and
      mechanisms of protein arginine methyltransferase 5 in the proliferation, cell
      cycle progression, and apoptosis of MDA-MB-231 cells were assessed using protein 
      arginine methyltransferase 5 and shPRMT5 transfection. In conclusion, we proposed
      that protein arginine methyltransferase 5 is an independent prognostic biomarker 
      for breast cancer, and targeting protein arginine methyltransferase 5 might be a 
      promising strategy for breast cancer treatment.
FAU - Wu, Ying
AU  - Wu Y
AD  - 1 Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth
      Military Medical University, Xi'an, P.R. China.
FAU - Wang, Zhe
AU  - Wang Z
AD  - 1 Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth
      Military Medical University, Xi'an, P.R. China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - 2 The State Key Laboratory of Cancer Biology, Department of Biochemistry and
      Molecular Biology, The Fourth Military Medical University, Xi'an, P.R. China.
FAU - Ling, Rui
AU  - Ling R
AD  - 1 Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth
      Military Medical University, Xi'an, P.R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - EC 2.1.1.319 (PRMT5 protein, human)
RN  - EC 2.1.1.319 (Protein-Arginine N-Methyltransferases)
SB  - IM
MH  - Apoptosis
MH  - Breast Neoplasms/enzymology/*mortality/pathology
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Female
MH  - Humans
MH  - Prognosis
MH  - Protein-Arginine N-Methyltransferases/analysis/*physiology
OTO - NOTNLM
OT  - Breast cancer
OT  - apoptosis
OT  - cell cycle progression
OT  - proliferation
OT  - protein arginine methyltransferase 5
EDAT- 2017/04/07 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/07 06:00
AID - 10.1177/1010428317695917 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Apr;39(4):1010428317695917. doi: 10.1177/1010428317695917.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>